Methotrexate Market Size By Indication (Psoriasis, Rheumatoid Arthritis, Cancer), By Mode (In-house, Contract Manufacturing), By Synthesis Type (Chemical Based API, Highly Potent API (HPAPI))

Description

List of Tables

The global methotrexate market is poised to record over 5% CAGR through 2032, propelled by the booming pharmaceutical sector. As healthcare priorities evolve, the demand for effective treatment options grows, highlighting the broadening spectrum of product's therapeutic applications.

The escalating incidence of chronic diseases is another main growth driver. As per a report by WHO in 2023, noncommunicable diseases (NCDs) claim the lives of 41 million individuals annually, representing 74% of global fatalities. Notably, 17 million people succumb to NCDs before the age of 70 years, with a substantial 86% of these premature deaths occurring in low- and middle-income countries. Methotrexate, a well-established disease-modifying antirheumatic drug (DMARD), has witnessed increased adoption due to its efficacy in managing autoimmune disorders such as rheumatoid arthritis and psoriasis. Furthermore, its role in cancer treatment, particularly in leukaemia and breast cancer, contributes significantly to the market growth.

The overall methotrexate market is classified based on indication, mode, synthesis type, and region.

The cancer segment is poised to witness significant gains during 2023-2032 driven by methotrexate's utility in chemotherapy protocols for leukaemia, breast cancer, and certain types of lymphomas. The continuous exploration of Methotrexate's potential in diverse cancer treatments underscores its importance as a cornerstone therapeutic agent in the oncology field.

The contract manufacturing segment is anticipated to witness robust growth during the forecast period. The pharmaceutical companies increasingly leverage contract manufacturing organizations (CMOs) to streamline production processes, enhance efficiency, and ensure compliance with regulatory standards. Collaborations with CMOs facilitate the seamless production and distribution of methotrexate, driving innovation and ensuring broader accessibility for patients globally.

Asia Pacific methotrexate market is expected to register swift growth through 2032 driven by the region's burgeoning population and evolving healthcare infrastructure. There is an increased prevalence of chronic diseases, driving the demand for effective treatment options. Countries like China and India, with their expanding pharmaceutical sectors, play a crucial role in the production and consumption of methotrexate, thereby shaping the regional market dynamics.

Product Code: 6835

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & workings
1.3 Forecast calculations
1.4 Data Sources
- 1.4.1 Primary
- 1.4.2 Secondary
  - 1.4.2.1 Paid sources
  - 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Global methotrexate market 360 degree synopsis, 2018 - 2032
2.2 Regional trends
2.3 Indication trends
2.4 Mode trends
2.5 Synthesis type trends

Chapter 3 Methotrexate Industry Insights

3.1 COVID- 19 impact analysis
3.2 Industry ecosystem analysis
3.3 Technology landscape
3.4 Regulatory landscape
3.5 Industry impact forces
- 3.5.1 Growth drivers
  - 3.5.1.1 Rising prevalence of chronic diseases
  - 3.5.1.2 Growing number of drug approvals by regulatory bodies
  - 3.5.1.3 Ongoing research and development using methotrexate drugs
  - 3.5.1.4 Rising technological advancements and demand for personalized medicine
- 3.5.2 Industry pitfalls & challenges
  - 3.5.2.1 Adverse effects and safety concerns
  - 3.5.2.2 Limited reimbursement and coverage policies
3.6 Growth potential analysis
- 3.6.1 By indication
- 3.6.2 By mode
- 3.6.3 By synthesis type
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
- 4.1.1 Novartis AG (Sandoz)
- 4.1.2 Merck & Co., Inc
- 4.1.3 Sun Pharmaceutical Industries Ltd
4.2 Competitive positioning matrix, 2022
4.3 Market share/ rank analysis
- 4.3.1 Global
- 4.3.2 North America
- 4.3.3 Europe
- 4.3.4 Asia Pacific
4.4 Production capacity
4.5 List of top 20 end consumers with contact details/email id

Chapter 5 Methotrexate Market Estimates and Forecast, By Indication (Revenue)

5.1 Key trends, by indication
5.2 Psoriasis
5.3 Rheumatoid arthritis
5.4 Cancer
5.5 Others

Chapter 6 Methotrexate Market Estimates and Forecast, By Mode (Revenue)

6.1 Key trends, by mode
6.2 In-house
6.3 Contract manufacturing

Chapter 7 Methotrexate Market Estimates and Forecast, By Synthesis Type (Revenue)

7.1 Key trends, by synthesis type
7.2 Chemical based API
7.3 Highly potent API (HPAPI)

Chapter 8 Methotrexate Market Estimates and Forecast, By Region (Revenue & Volume)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Russia
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Malaysia
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE

Chapter 9 Company Profiles

9.1 Teva Pharmaceutical Industries Ltd
9.2 Sun Pharmaceutical Industries Ltd
9.3 Aurobindo Pharma Ltd
9.4 Lonza Group AG
9.5 Merck & Co., Inc
9.6 Fermion (Orion Corporation)
9.7 Avra Laboratories Pvt Ltd
9.8 Rochem International Inc
9.9 LGM Pharm
9.10 Sandoz AG (Novartis AG)